Improved safety and efficacy of AmBisome (liposomal amphotericin B, L-AmB) vs. amphotericin B (CAB) in the empirical treatment of febrile neutropenic patients undergoing BMT.

被引：0
|
作者：
Cagnoni, PJ [1 ]
Grethlein, S [1 ]
Korones, DN [1 ]
Goldman, M [1 ]
Kaizer, H [1 ]
机构：
[1] Empir Antifungal Study Grp, Denver, CO USA
来源：
BONE MARROW TRANSPLANTATION | 1999年 / 23卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
361
引用
收藏
页码：S112 / S112
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of Ambisome (AMB) vs amphotericin B (AMPHOB) in the empiric treatment of febrile neutropenia in adults and children.
    Boogaerts, M
    Tormans, G
    Maes, E
    VanDoorslaer, B
    BLOOD, 1996, 88 (10) : 1994 - 1994
  • [22] Liposomal amphotericin B (L-AMB) is superior to amphotericin B deoxycholate (AmB-d) in preventing breakthrough fungal infections in patients with prolonged neutropenia and fever: Results of a sub-group analysis of an empirical antifungal therapy trial.
    Cordonnier, C
    Walsh, TJ
    Bresnik, M
    BLOOD, 2004, 104 (11) : 376A - 376A
  • [23] A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia
    Wingard, JR
    White, MH
    Anaissie, E
    Raffalli, J
    Goodman, J
    Arrieta, A
    CLINICAL INFECTIOUS DISEASES, 2000, 31 (05) : 1155 - 1163
  • [24] Efficacy and safety of high doses of liposomal amphotericin B (Ambisome®) in treatment of patients with invasive fungal (I.F) infection.
    Buffels, R
    Beaman, M
    Golledge, C
    Heath, C
    Hertzberg, M
    Ward, S
    Wilson, M
    Cornille, H
    Dupuis, S
    Farhat, S
    Gandemer, V
    Hulin, C
    Minckes, O
    Parquet, N
    Anttila, VJ
    Catrin-Nikolakaki, D
    Papadakkis, V
    Saroglou, G
    Giladi, M
    Keller, N
    Leibovitz, E
    Nagler, A
    Oren, I
    De Simone, M
    Donelli, A
    Pession, A
    Bodell, I
    Fernandez, A
    Ginovert, G
    Gonzales, V
    Guinea, GM
    Lacruz, J
    Lopez, M
    Quintana
    Ramacho, R
    Billingue, V
    Prentice, H
    BLOOD, 2000, 96 (11) : 785A - 785A
  • [25] MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FOR EMPIRICAL ANTIFUNGAL THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RANDOMIZED CONTROLLED TRIAL
    Oyake, T.
    Sugawara, N.
    Fujisawa, Y.
    Sasaki, R.
    Izumida, W.
    Mine, T.
    Asahi, M.
    Suzuki, Y.
    Okano, Y.
    Fujishima, Y.
    Tsukushi, Y.
    Aoki, Y.
    Kowata, S.
    Hanamura, I.
    Murai, K.
    Ito, S.
    Ishida, Y.
    HAEMATOLOGICA, 2017, 102 : 253 - 253
  • [26] COMPARISON OF MICAFUNGIN AND LIPOSOMAL AMPHOTERICIN B FOR EMPIRICAL ANTIFUNGAL THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RANDOMIZED CONTROLLED TRIAL
    Fujisawa, Y.
    Oyake, T.
    Sugawara, N.
    Sasaki, R.
    Tsukushi, Y.
    Hanamura, I.
    Fujishima, Y.
    Aoki, Y.
    Kowata, S.
    Ito, S.
    Ishida, Y.
    HAEMATOLOGICA, 2015, 100 : 135 - 135
  • [27] Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis
    Lanternier, F.
    Poiree, S.
    Elie, C.
    Garcia-Hermoso, D.
    Bakouboula, P.
    Sitbon, K.
    Herbrecht, R.
    Wolff, M.
    Ribaud, P.
    Lortholary, O.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (11) : 3116 - 3123
  • [28] Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study
    Azoulay, Elie
    Timsit, Jean-Francois
    Lautrette, Alexandre
    Legriel, Stephane
    Max, Adeline
    Ruckly, Stephane
    Misset, Benoit
    Cohen, Yves
    Wolff, Michel
    PLOS ONE, 2017, 12 (05):
  • [29] Efficacy outcomes in a randomized trial of liposomal amphotericin B (L-AMB) based on Revised EORTC/MSG 2008 definitions of invasive fungal disease (IFD)
    Cornely, O. A.
    Maertens, J.
    Bresnik, M.
    Ebrahimi, R.
    Dellow, E.
    Herbrecht, R.
    Donnelly, P. J.
    MYCOSES, 2009, 52 : 83 - 83
  • [30] LIPOSOMAL AMPHOTERICIN-B (AMBISOME) TREATMENT IN SOLID ORGAN AND BONE-MARROW TRANSPLANT RECIPIENTS - EFFICACY AND SAFETY EVALUATION
    TOLLEMAR, J
    RINGDEN, O
    TYDEN, G
    CLINICAL TRANSPLANTATION, 1990, 4 (03) : 167 - 175
12345